Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Webman, Edward J (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S964000
Reexamination Certificate
active
07087619
ABSTRACT:
Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.
REFERENCES:
patent: 4645758 (1987-02-01), Willman et al.
patent: 4806543 (1989-02-01), Choi
patent: 4865843 (1989-09-01), Nepon
patent: 4877791 (1989-10-01), Sherman
patent: 4906638 (1990-03-01), Pontecorvo et al.
patent: 5080905 (1992-01-01), Pestellini et al.
patent: 5145859 (1992-09-01), Fleischmann
patent: 5166207 (1992-11-01), Smith
patent: 5180715 (1993-01-01), Parsons
patent: 5192751 (1993-03-01), Thor
patent: 5206248 (1993-04-01), Smith
patent: 5229394 (1993-07-01), Salazar-Grueso
patent: 5233053 (1993-08-01), Cross et al.
patent: 5236956 (1993-08-01), Sjögren et al.
patent: 5252589 (1993-10-01), Ozeki et al.
patent: 5258390 (1993-11-01), Ohnmacht
patent: 5266596 (1993-11-01), Yokokawa et al.
patent: 5272163 (1993-12-01), Russell et al.
patent: 5340805 (1994-08-01), Harrington, Jr.
patent: 5340819 (1994-08-01), Ohnmacht et al.
patent: 5340826 (1994-08-01), Rosen et al.
patent: WO 96/27375 (1996-09-01), None
The Merck Manual of Diagnosis and Therapy, 15th Edition, Edited by Berkow et al., Published by Merck Sharp & Dohme Research Laboratories, Chapter 13, Sections 158-159 (1987).
The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th Edition, Edited by Budavari et al., Published by Merck & Co., Inc., Entries: 3392, 5350 and 8116 (1989).
Takimoto et al. Clinical Effectiveness of KL 007 (Oxybutynin HCl) in Urinary Disorders. Hinyokika-Kiyo, 31(12), pp. 2284-2301. Dec. 1985. Abstract Only.
Andersson, K.E. Current Concepts in the Treatment of Disorders of Micturition. Drugs, 35(4), pp. 477-494. (Apr. 1988). Abstract Only.
Nagy et al. Idiopathic Bladder Hyperactivity Treated with Ditropan (Oxybutynin Chloride). Int.-Urol.-Nephrol., 22(6), pp. 519-524. (1990). Abstract Only.
Yokoyama et al. Clinical Effect of Oxybutynin HCl (1mg/Tablet). Hinyokika-Kiyo, 36(7), pp. 869-876. (Jul. 1990). Abstract Only.
Thuroff et al. Randomized, Double-Blind, Multicenter Trial on Treatment of Frequency, Urgency and Incontinence Related to Detrusor Hyperactivity: Oxybutynin Versus Propantheline Versus Placebo.
The Journal of Urology, vol. 145, No. 4, pp. 813-817. (Apr. 1991).
Dray et al., “Opioids and Central Inhibition of Urinary Bladder Motility”, European Journal of Pharmacology, Feb. 1984, vol. 98, No. 1, pp. 155-156.
Dray et al., “Morphine and the Centrally-Mediated Inhibition of Urinary Bladder Motility in the Rat”, Brain Research, vol. 297, No. 1, pp. 191-195 (1984).
Dray et al., “Inhibition of Urinary Bladder Contractions by a Spinal Action of Morphine and other Opioids”, J. Pharmacol Exp Ther., vol. 231, No. 2, pp. 254-260 (1984).
Tortella-FC, et al., “Dextromethorphan and Neuromodulation: Old Drug Coughs Up New Activities”, Trends-Pharmacol-Sci., Published in Dec. 1989; vol. 10(12): pp. 501-507.
Maggi-CA, et al., “The Effect of MK-801 on the Micturition Reflex in Anesthetized Rats”, Eur-J-Pharmacol., Published in May 31, 1990, vol. 181(1-2): pp. 105-109.
Yamauchi-K, et al., “Clinical Effects of Oxybutynin Hydrochloride (Pollakis)—Especially in the Treatment of Pollakisuria, Urgency and Urinary Incontinence”.
Hinyokika-Kiyo., Published in Dec. 1990, vol. 36(12): pp. 1485-1490.
Yoshiyama et al., “The effects of MK-801, an NMDA Receptor Antagonist, on the Micturition Reflex in the Rat”, Neurosci-Lett., Published in May 27, 1981, vol. 126(2): pp. 141-144.
Yoshiyama-M, et al., “Effects of MK-801 on the Micturition Reflex in the Rat—Possible Sites of Action”, J-Pharmacol-Exp-Ther., Published in May 1993; vol. 265(2): pp. 844-850.
Akaike-N, et al., “Antagonism of Various Tonic Convulsions in Mice by Dextrorphan and Dizocilpine”, Naunyn-Schmiedebergs-Arch-Pharmacol., Published in Jun. 1993, vol. 347(6): pp. 652-657.
Himori-N, et al., “Dextrorphan Attenuates the Behavioral Consequences of Ischemia and the Biochemical Consequences of Anoxia: Possible Role of N-Methyl-D-Aspartate Receptor Antagonism and ATP Replenishing Action in its Cerebroprotecting Profile”, Psychopharmacology-Berl., Published in 1993, vol. 111(2): pp. 153-162.
Yoshiyama-M, et al., “Effects of LY274614, a Competitive NMDA Receptor Antagonist, on the Micturition Reflex in the Urethane-Anaesthetized Rat”, Br-J-Pharmacol., Sep. 1993; 110(1): pp. 77-86.
Carter-AJ, “Many Agents that Antagonize the NMDA Receptor-Channel Complex in Vivo Also Cause Disturbances of Motor Coordination”, J-Pharmacol-Exp-Ther., May 1994; 269(2): pp. 573-580.
Yoshiyama-M, et al., “Alteration by Urethane of Glutamatergic Control of Micturition”, Eur-J-Pharmacol., Published in Nov. 3, 1994; vol. 264(3): pp. 417-425.
Matsumoto-G, et al., “Role of Glutamate and NMDA Receptors in the Descending Limb of the Spinobulbospinal Micturition Reflex Pathway of the Rat”, Neurosci-Lett., Jan. 1995, 183(1-2): pp. 58-61.
The Merck Manual of Diagnosis and Therapy, 15th Edition, Edited by Berkow et al., Published by Merck Sharp & Dohme Research Laboratories, Chapter 13, Sections 158-159 (1987).
The Merck Manual of Diagnosis and Therapy, 15th Edition, Edited by Berkow et al., Published by Merck Sharpe & Dohme Research Laboratories, Chapter 13, Sec. 153, p. 1621.
The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th Edition, Edited by Budavari et al., Published by Merck & Co., Inc., Entries: 3392, 5350 and 8116 (1989).
Lecci et al., Involvement of spinal tachykinin NK1and NK2receptors in detrusor hyperreflexis during chemical cystitis in anaesthetized rats, European Journal of Pharmacology, 259 (1994) 129-135.
Rice et al., Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP-5) prevents hyper-reflexia in a model of persistent visceral pain, Pain, 57 (1994) 335-340.
Quick Reference Guide for Clinicians, “Urinary Incontinence in Adults”, AHCPR Pub. No. 92-0041, Agency for Health Care Policy and Research, Public Health Service, U.S. Dept. of Health and Human Services, Mar. 1992.
Dilworth & Barrese LLP
Endo Pharmaceuticals Inc.
Webman Edward J
LandOfFree
Method for the treatment of urinary incontinence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of urinary incontinence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of urinary incontinence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3661132